Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10634002 | 1.00 | L3MBTL1 (0.32) | L3MBTL1HDAC6KMT2AMEN1GAA | |
| SCHEMBL21403608 | 1.00 | L3MBTL1 (0.32) | L3MBTL1HDAC6KMT2AMEN1GAA | |
| SCHEMBL21403646 | 0.86 | HDAC6 (0.31) | HDAC6KMT2AMEN1DPP4 | |
| SCHEMBL25838348 | 0.85 | MEN1 (0.36) | L3MBTL1HDAC6KMT2AMEN1NPSR1 | |
| SCHEMBL21930562 | 0.84 | MEN1 (0.38) | L3MBTL1HDAC6KMT2AMEN1DPP4 | |
| SCHEMBL21930560 | 0.84 | MEN1 (0.38) | L3MBTL1HDAC6KMT2AMEN1DPP4 | |
| SCHEMBL21403728 | 0.83 | SMN1; SMN2 (0.38) | HDAC6KMT2AMEN1HDAC1HDAC2 | |
| SCHEMBL21403730 | 0.83 | SMN1; SMN2 (0.38) | HDAC6KMT2AMEN1HDAC1HDAC2 | |
| SCHEMBL25165313 | 0.82 | HDAC6 (0.33) | L3MBTL1HDAC6KMT2AMEN1NPSR1 | |
| SCHEMBL21930316 | 0.81 | L3MBTL1 (0.31) | L3MBTL1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230010358-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| US-20230010358-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| EP-3774843-B1 | DIPEPTIDE PIPERIDINE DERIVATIVES | MOLECURE SA (PL) | 2022-05-25 | — | — | EP | disclosed |
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-09-28 | — | — | US | disclosed |
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-09-28 | — | — | US | disclosed |
| EP-3877390-A1 | SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | Prelude Therapeutics, Incorporated (US) | 2021-09-15 | — | — | EP | disclosed |
| CN-113166173-A | Spiro-sulfonamide derivatives as inhibitors of myeloid leukemia 1(MCL-1) protein | 普莱鲁德疗法有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-10851099-B2 | Dipeptide piperidine derivatives | Oncoarendi Therapeutics S.A. (PL) | 2020-12-01 | — | — | US | disclosed |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2020-05-14 | — | — | US | disclosed |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2020-05-14 | — | — | US | disclosed |
| US-20190300525-A1 | DIPEPTIDE PIPERIDINE DERIVATIVES | Oncoarendi Therapeutics S.A. (PL) | 2019-10-03 | — | — | US | disclosed |
| EP-0649414-B1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | ARDENT PHARMACEUTICALS INC (US) | 2003-04-16 | — | — | EP | disclosed |
| US-5854249-A | Opioid diarylmethylpiperazines and piperidines | DELTA PHARMACEUTICALS, INC. (US) | 1998-12-29 | — | — | US | disclosed |
| US-5658908-A | RECEPTOR BINDING SPECIES FOR MEDIATING ANALGESIA, COMBATTING DRUG ADDICTION, DRUG OVERDOSE | DELTA PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0649414-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-04-26 | — | — | EP | disclosed |
| WO-1993015062-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
| US-4760180-A | N-terminally substituted dipeptide amides | G. D. SEARLE & CO. (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0213481-A2 | N-terminally substituted dipeptide amides No. 2 | G.D. Searle & Co. (US) | 1987-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | MCL1, BCL2A1, BCL2L1 | L3MBTL1 2559/4885HDAC6 116/4885KMT2A 1574/4885 |
| US-10851099-B2 | Dipeptide piperidine derivatives | ARG1, ARG2, PEPD | L3MBTL1 3926/4885HDAC6 706/4885KMT2A 2932/4885 |
| US-20190300525-A1 | DIPEPTIDE PIPERIDINE DERIVATIVES | ARG1, ARG2, PEPD | L3MBTL1 3926/4885HDAC6 706/4885KMT2A 2932/4885 |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | MCL1, BCL2A1, BCL2L1 | L3MBTL1 2559/4885HDAC6 116/4885KMT2A 1574/4885 |
| US-20230010358-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | MCL1, BCL2A1, BCL2L1 | L3MBTL1 2559/4885HDAC6 116/4885KMT2A 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.